Danish drugmaker Novo Nordisk has been suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years over what the ABPI on Thursday described as 'serious breaches' of its code of practice.
"While we are disappointed with this outcome, we accept the decision. We will remain committed to following the ABPI Code of Practice and maintaining the highest possible ethical standards required by the pharmaceutical industry," a company spokesperson said.
The suspension follows the departure of Pinder Sahota, Novo's British business head, who resigned from his role as ABPI president last month to avoid the breach becoming a "distraction" from the association's "vital work" while the complaint was being investigated. Novo is the market leader in the rapidly growing area of weight loss through medicinal treatment rather than only dieting or exercising.
Wealthy nations are grappling with fast-climbing rates of obesity and related conditions such as type 2 diabetes and heart disease. Saxenda is an older drug that has been approved for weight loss. Novo has since developed a more effective obesity treatment called Wegovy, which has been in
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Novo Nordisk plans price cuts for several insulinsNovo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly.
Leer más »
Following Eli Lilly, drugmaker Novo Nordisk announces cuts to insulin pricesBREAKING: Novo Nordisk says it will lower the U.S. list price of some of its insulin products by up to 75% starting Jan. 1, 2024, following a similar move by Eli Lilly.
Leer más »
Novo Nordisk plans to cut insulin prices up to 75%, following Eli LillyNovo will reduce the list price for NovoLog and NovoLog Mix 70/30 by 75%, and cut Novolin and Levemir’s list prices by 65% — but not until 2024.
Leer más »
Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli LillyNovo Nordisk is planning to slash the price of several insulin drugs by up to 75% in the U.S., following a similar move by Eli Lilly.
Leer más »
Novo Nordisk to Slash Insulin Prices by Up to 75%Novo Nordisk has announced plans to slash the price of several insulin drugs by up to 75% in the U.S., becoming the latest drugmaker to make sharp price cuts after years of public outrage over the high cost of diabetes care.
Leer más »